'Fresh options' for BioSenic after post-hoc analysis of knee osteoarthritis trial
BioSenic (Euronext: BIOS), a Belgian firm specializing in severe inflammatory diseases and cellular repair, has announced that it has re-evaluated the results of its Phase III trial of the enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA).
New statistical analysis results from the JTA-004 Phase III trial data, released in August 2021, have been obtained by BioSenic, which was formerly known as Bone Therapeutics.
The study, which was conducted in seven European countries and Hong Kong and included a total of 743 patients, did not meet the primary and consequently the key secondary endpoints, despite JTA-004’s favorable safety profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze